TABLE 2.
Participant characteristics (mITT population)
| Pooled ACHIEVE participants | ||
|---|---|---|
| Placebo | Ubrogepant 50 mg | |
| (n = 912) | (n = 887) | |
| Triptan responder, N | 350 | 332 |
| Age, mean (SD), y | 44.4 (12.5) | 44.0 (11.4) |
| Female, n (%) | 318 (90.9) | 307 (92.5) |
| White, n (%) | 312 (89.1) | 303 (91.3) |
| BMI, mean (SD), kg/m2 | 28.3 (6.3) | 29.2 (7.3) |
| Moderate/high CV risk, n (%) | 27 (7.7) | 31 (9.3) |
| Triptan‐insufficient responder, N | 223 | 228 |
| Age, mean (SD), y | 40.1 (10.7) | 38.4 (10.7) |
| Female, n (%) | 206 (92.4) | 214 (93.9) |
| White, n (%) | 192 (86.1) | 189 (82.9) |
| BMI, mean (SD), kg/m2 | 30.1 (7.9) | 31.1 (8.4) |
| Moderate/high CV risk, n (%) | 32 (14.3) | 24 (10.5) |
| Triptan naive, N | 339 | 327 |
| Age, mean (SD), y | 38.4 (11.2) | 38.2 (12.7) |
| Female, n (%) | 285 (84.1) | 282 (86.2) |
| White, n (%) | 250 (73.8) | 236 (72.2) |
| BMI, mean (SD), kg/m2 | 31.5 (8.2) | 30.9 (7.7) |
| Moderate/high CV risk, n (%) | 33 (9.7) | 37 (11.3) |
Abbreviations: BMI, body mass index; CV, cardiovascular; mITT, modified intent‐to‐treat; SD, standard deviation.